Bioatla Stock Today
| BCAB Stock | USD 0.27 0.02 7.24% |
PerformanceWeakest
| Odds Of DistressRisky
|
Bioatla is trading at 0.26899999 as of the 31st of January 2026, a 7.24 percent decrease since the beginning of the trading day. The stock's open price was 0.29. Bioatla has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 2nd of November 2025 and ending today, the 31st of January 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of December 2020 | Category Healthcare | Classification Health Care |
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California. Bioatla operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 64.04 M outstanding shares of which 4.74 M shares are currently shorted by private and institutional investors with about 2.1 trading days to cover. More on Bioatla
Moving against Bioatla Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Bioatla Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBioatla can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bioatla's financial leverage. It provides some insight into what part of Bioatla's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bioatla (BCAB) is traded on NASDAQ Exchange in USA and employs 61 people. Bioatla is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 18.44 M. Bioatla conducts business under Biotechnology sector and is part of Health Care industry. The entity has 64.04 M outstanding shares of which 4.74 M shares are currently shorted by private and institutional investors with about 2.1 trading days to cover.
Bioatla currently holds about 178.12 M in cash with (71.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Bioatla Probability Of Bankruptcy
Ownership AllocationBioatla holds a total of 64.04 Million outstanding shares. Bioatla shows 11.07 percent of its outstanding shares held by insiders and 28.6 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Bioatla Ownership Details
Bioatla Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Marshall Wace Asset Management Ltd | 2025-06-30 | 80.8 K | |
| Susquehanna International Group, Llp | 2025-06-30 | 74.8 K | |
| Magnus Financial Group Llc | 2025-06-30 | 47.2 K | |
| Mccormack Advisors International | 2025-06-30 | 44.3 K | |
| Alpha Cubed Investments Llc | 2025-06-30 | 41.1 K | |
| National Asset Management Inc | 2025-06-30 | 30 K | |
| Ubs Group Ag | 2025-06-30 | 29.6 K | |
| Columbia Advisory Partners Llc | 2025-06-30 | 26.1 K | |
| Commonwealth Equity Services Inc | 2025-06-30 | 25.3 K | |
| Vanguard Group Inc | 2025-06-30 | 1.8 M | |
| Tang Capital Management Llc | 2025-06-30 | 1.4 M |
Bioatla Historical Income Statement
Bioatla Stock Against Markets
Bioatla Corporate Management
| Gerhard Frey | Senior Development | Profile | |
| Cathy Chang | Senior Development | Profile | |
| Christian CPA | Controller Officer | Profile | |
| Sheri Lydick | Chief Officer | Profile | |
| Philippe Martin | Chief Operations | Profile | |
| Monica Sullivan | Senior Contracts | Profile | |
| Christian Vasquez | Controller Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bioatla. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Bioatla Stock refer to our How to Trade Bioatla Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bioatla. Projected growth potential of Bioatla fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Bioatla assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Bioatla is measured differently than its book value, which is the value of Bioatla that is recorded on the company's balance sheet. Investors also form their own opinion of Bioatla's value that differs from its market value or its book value, called intrinsic value, which is Bioatla's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bioatla's market value can be influenced by many factors that don't directly affect Bioatla's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Bioatla's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bioatla should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Bioatla's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.